RecruitingNot applicableNCT07682597
Official study title

Statewide Optimization of Lung Cancer Screening Utilizing the QUILS™ System in Nevada and Mississippi: State-Based Initiative Component

Study summary

This clinical trial studies whether a Quality Implementation of Lung Cancer Screening (QUILS™) System state-based initiative (SBI) intervention works to improve the statewide capacity for implementing and sustaining lung cancer screening in Mississippi (MS) and Nevada (NV). The QUILS™ Group is focused on fair and high-quality implementation of lung cancer screening among eligible individuals to reduce lung cancer-related death in underserved communities. Previous research had success with implementing interventions in Kentucky which has lead to significant increases in lung cancer screening rates and a rapid decline in late-stage lung cancer diagnoses within the state. The goal is to offer the opportunity to replicate this work in states which are eager to address suboptimal screening rates, high lung cancer-related death, and significant health equity concerns. The QUILS™ SBI intervention involves translating the success of the initial work in Kentucky to impact lung cancer screening implementation and lung cancer outcomes in MS and NV through close collaboration with state-based partners. The QUILS™ SBI intervention may be an effective way to improve the statewide capacity for implementing and sustaining lung cancer screening in MS and NV.

Ask AI to explain this study
Start here

Key things to know

Main goalScreening

This describes the study’s primary purpose.

What is being studiedQUILS SBI Intervention

The study team can explain what participation involves.

Who it may be forLung Cancer Screening

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 6, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?13 U.S. locations

Locations may change over time.

Who runs it?Timothy Mullett

Study sponsor

01
Study overview

What this study is about

Purpose
Screening
Study type
Interventional
Phase
Not applicable
Sponsor
Timothy Mullett
Interventions being studied
Behavioral: QUILS SBI Intervention
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Member of a state-based lung cancer screening implementation team in Mississippi or Nevada.
  • Leadership member of the Mississippi state team or Nevada state team
  • Active member of the Mississippi Lung Cancer Roundtable (MSLCRT) or Nevada Lung Cancer Coalition (NLCC)
  • Willing to participate in study-related assessments an implementation activities
Reasons someone may not be able to joinExclusion criteria

None

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Delta Health SystemGreenville, Mississippi
  • Greenwood Leflore HospitalGreenwood, Mississippi
  • Memorial Hospital GulfportGulfport, Mississippi
  • Hattiesburg ClinicHattiesburg, Mississippi
  • University of Mississippi Medical CenterJackson, Mississippi
  • Baptist Memorial HospitalNew Albany, Mississippi
  • North Mississippi Health ServicesTupelo, Mississippi
  • Mt. Grant General HospitalHawthorne, Nevada
  • Desert View HospitalPahrump, Nevada
  • Renown Regional Medical CenterReno, Nevada
  • Sierra Medical CenterReno, Nevada
  • Sunrise HealthWinchester, Nevada

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 6, 2026. Always confirm current availability with the study team.

View original record ↗